Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bdd9518495352cf9f926423d466b9e84 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7236f9e49d1c6839766fa9d36d228236 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8ffdd0403966b3257cdff37810d77910 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f35ac110f88fb11dae3b9ebcdcb0d7fa |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5748 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-215 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
filingDate |
2012-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2016-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd10438e61db84babb9111c8ef35b2f9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b096683db191847bb63fa5efd8a23897 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4025cf56bf58d925676554caa6a4c153 |
publicationDate |
2016-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-9383364-B2 |
titleOfInvention |
Predictive marker of DNMT1 inhibitor therapeutic efficacy and methods of using the marker |
abstract |
Provided herein are methods for predicting efficacy of a DNA (cytosine-5)-methyltransferase 1 (DNMT1) inhibitor treatment in a subject having a cancer, methods of identifying a subject having a cancer that is more likely to respond to a DNMT1 inhibitor treatment, and methods of selecting a treatment for a subject having a cancer that include determining a level of SOX9 in a sample containing cells from a subject having a cancer. Also provided are methods of treating a subject having a cancer that include selectively administering a DNMT1 inhibitor to a subject having cancer determined to have an elevated level of SOX9 in a sample containing cells from the subject compared to a reference level. Also provided are antibodies and antigen-binding antibody fragments that specifically bind to SOX9, and nucleic acid sequences that contain at least 10 nucleotides complementary to a contiguous sequence present in a SOX9 nucleic acid for use in these methods. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11679098-B2 |
priorityDate |
2011-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |